<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669862</url>
  </required_header>
  <id_info>
    <org_study_id>A-101-WART-201</org_study_id>
    <nct_id>NCT02669862</nct_id>
  </id_info>
  <brief_title>A Study of A-101 Solution in Subjects With Common Warts.</brief_title>
  <official_title>A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Solution in Subjects With Common Warts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aclaris Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aclaris Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment
      groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment
      groups. During Visit 1, the Investigator will identify 1 eligible common wart on the trunk or
      extremities on each subject. The wart will be treated up to a maximum of 8 times at 1 week
      intervals during the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 21, 2015</start_date>
  <completion_date type="Actual">September 16, 2016</completion_date>
  <primary_completion_date type="Actual">September 16, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Based on Mean Change in Physician Wart Assessment Over Time</measure>
    <time_frame>57 Days</time_frame>
    <description>The primary effectiveness will consist of the mean change from Visit 2 to Visit 10 in Physician Wart Assessment (PWA) performed using Analysis of Covariance (ANCOVA) with Visit 2 PWA as the covariate. Physician Wart Analysis is a measurement scale from 0 to 3 that evaluates the wart with 0 being clear and 3 being clinically diagnosable wart that is raised, with an obviously rough surface.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of Response - Percentage of Participants That Were Clear at Visit 10 That Are Still Clear at Visit 13</measure>
    <time_frame>visit 10 to visit 13</time_frame>
    <description>Percentage of subjects whose target wart was clear at Visit 10 and who remained clear at Visit 13 for active treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PWA Responder</measure>
    <time_frame>Day 57</time_frame>
    <description>The percentage of participants who were responders with the target wart judged to be clear (PWA = 0) at Visit 10.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Common Warts</condition>
  <arm_group>
    <arm_group_label>A-101 Solution 40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-101 Solution 40% administered once per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-101 Solution 45</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-101 Solution 45% administered once per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Solution administered once per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-101 Solution 40</intervention_name>
    <arm_group_label>A-101 Solution 40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-101 Solution 45</intervention_name>
    <arm_group_label>A-101 Solution 45</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Solution</intervention_name>
    <arm_group_label>Vehicle Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is at least 18 years of age

          2. Subject has a clinical diagnosis of common warts

          3. Subject has 1 appropriate Target Wart as defined below, on the trunk or extremities:

               -  Have a longest axis that is 3mm to 10mm

               -  Have a thickness ≤3mm

               -  Be a discrete lesion

               -  Be, when centered in the circular cutout of the provided template, the only
                  common wart present

               -  Not be periungual, subungual, genital or anal

               -  Not be covered with hair which, in the Investigator's opinion, would interfere
                  with the study medication treatments or the study evaluations Not be in an area
                  that may be occluded (by clothing, footwear or within a skin fold).

          4. The Target Wart has a Physician Wart Assessment (PWA) ≥2

          5. If the subject is a woman of childbearing potential, she has a negative urine
             pregnancy test and agrees to use an approved effective method of birth control for the
             duration of the study

          6. Subject is non-pregnant and non-lactating

          7. Subject is in good general health and free of any known disease state or physical
             condition which, in the Investigator's opinion, might put the subject at undue risk by
             study participation or interfere with the study conduct or evaluations

          8. Subject is willing and able to follow all study instructions and to attend all study
             visits

          9. Subject is able to comprehend and willing to sign an Informed Consent Form.

        Exclusion Criteria:

          1. Subject has clinically atypical warts on the trunk or extremities

          2. Subject is immune compromised (due to chemotherapy, systemic steroids, genetic
             immunodeficiency, transplant status, etc.)

          3. Subject has a history of Human Immunodeficiency Virus (HIV) infection

          4. Subject has had any Human Papilloma Virus (HPV) vaccine within 1 year prior to
             enrollment

          5. Subject has used any of the following intralesional therapies within the specified
             period prior to enrollment to the Target Wart:

               -  Immunotherapy (Candida antigen, mumps antigen, Trichophyton antigen);

               -  Anti-metabolite therapy (bleomycin, 5-fluorouracil)

          6. Subject has used any of the following systemic therapies within the specified period
             prior to enrollment:

               -  Immunomodulatory/immunosuppressant therapy (e.g., etanercept, alefacept,
                  infliximab);

               -  Glucocortico-steroids (inhaled and intra-nasal steroids are permitted);

          7. Subject has used any of the following topical therapies within the specified period
             prior to enrollment on, or in a proximity to the Target Wart, which in the
             Investigator's opinion, might put the subject at undue risk by study participation or
             interfere with the study conduct or evaluations:

             - LASER (pulsed-dye laser), light (intense pulsed light, photo-dynamic therapy, other
             energy based therapy); Immuno-therapy ( imiquimod, squaric acid dibutyl ester, etc.);
             Anti-metabolite therapy (5-fluorouracil); Retinoids; Liquid nitrogen,
             electrodesiccation, curettage; Over-the-counter wart therapies

          8. Subject has had any of the following within the specified period prior to enrollment
             on, or in a proximity to the target lesion, which in the Investigator's opinion, might
             put the subject at undue risk by study participation or interfere with the study
             conduct or evaluations:

               -  A cutaneous malignancy;

               -  A pre-malignancy (actinic keratosis)

          9. Subject has a history of sensitivity to any of the ingredients in the study
             medications

         10. Subject has any current skin disease (psoriasis, atopic dermatitis, eczema, sun
             damage, etc.), skin condition (sunburn, open wounds) or other disease or condition
             (uncontrolled diabetes) which, in the Investigator's opinion, might put the subject at
             undue risk by study participation or interfere with the study conduct or evaluations

         11. Subject has participated in an investigational drug trial in which administration of
             an investigational study medication occurred within 30 days prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart D Shanler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aclaris Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aclaris Therapeutics, Inc.</name>
      <address>
        <city>Wayne</city>
        <state>Pennsylvania</state>
        <zip>19087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <results_first_submitted>April 4, 2018</results_first_submitted>
  <results_first_submitted_qc>November 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 7, 2018</results_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A-101 Solution 40</title>
          <description>A-101 Solution 40% administered once per week
A-101 Solution 40</description>
        </group>
        <group group_id="P2">
          <title>A-101 Solution 45</title>
          <description>A-101 Solution 45% administered once per week
A-101 Solution 45</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Solution</title>
          <description>Vehicle Solution administered once per week
Vehicle Solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A-101 Solution 40</title>
          <description>A-101 Solution 40% administered once per week
A-101 Solution 40</description>
        </group>
        <group group_id="B2">
          <title>A-101 Solution 45</title>
          <description>A-101 Solution 45% administered once per week
A-101 Solution 45</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Solution</title>
          <description>Vehicle Solution administered once per week
Vehicle Solution</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="16.40"/>
                    <measurement group_id="B2" value="41.2" spread="14.11"/>
                    <measurement group_id="B3" value="39.5" spread="13.37"/>
                    <measurement group_id="B4" value="40.7" spread="14.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Percentages are based on the number of randomized subjects within each treatment group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Based on Mean Change in Physician Wart Assessment Over Time</title>
        <description>The primary effectiveness will consist of the mean change from Visit 2 to Visit 10 in Physician Wart Assessment (PWA) performed using Analysis of Covariance (ANCOVA) with Visit 2 PWA as the covariate. Physician Wart Analysis is a measurement scale from 0 to 3 that evaluates the wart with 0 being clear and 3 being clinically diagnosable wart that is raised, with an obviously rough surface.</description>
        <time_frame>57 Days</time_frame>
        <population>Number of participants analyzed is the number of participants completing the protocol through visit 10.</population>
        <group_list>
          <group group_id="O1">
            <title>A-101 Solution 40</title>
            <description>A-101 Solution 40% administered once per week
A-101 Solution 40</description>
          </group>
          <group group_id="O2">
            <title>A-101 Solution 45</title>
            <description>A-101 Solution 45% administered once per week
A-101 Solution 45</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Solution</title>
            <description>Vehicle Solution administered once per week
Vehicle Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Based on Mean Change in Physician Wart Assessment Over Time</title>
          <description>The primary effectiveness will consist of the mean change from Visit 2 to Visit 10 in Physician Wart Assessment (PWA) performed using Analysis of Covariance (ANCOVA) with Visit 2 PWA as the covariate. Physician Wart Analysis is a measurement scale from 0 to 3 that evaluates the wart with 0 being clear and 3 being clinically diagnosable wart that is raised, with an obviously rough surface.</description>
          <population>Number of participants analyzed is the number of participants completing the protocol through visit 10.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.75"/>
                    <measurement group_id="O2" value="-1.00" spread="0.97"/>
                    <measurement group_id="O3" value="-0.44" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In this table Study Day 01 / Visit 2 has been considered as Baseline visit for calculating mean and mean change.
PVal*- ANCOVA used for calculating P-value by comparing Vehicle against each Active treatment group using baseline values as the covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.555</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline values were the covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In this table Study Day 01 / Visit 2 has been considered as Baseline visit for calculating mean and mean change.
PVal*- ANCOVA used for calculating P-value by comparing Vehicle against each Active treatment group using baseline values as the covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>PVal*- ANCOVA used for calculating P-value by comparing Vehicle against each Active treatment group using baseline values as the covariate. No adjustments for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Durability of Response - Percentage of Participants That Were Clear at Visit 10 That Are Still Clear at Visit 13</title>
        <description>Percentage of subjects whose target wart was clear at Visit 10 and who remained clear at Visit 13 for active treatment groups</description>
        <time_frame>visit 10 to visit 13</time_frame>
        <population>Only the number of participants clear at visit 10 are compared to the number of participants clear at visit 13 to get the percentage clear for active treatment groups only.</population>
        <group_list>
          <group group_id="O1">
            <title>A-101 Solution 40</title>
            <description>A-101 Solution 40% administered once per week
A-101 Solution 40</description>
          </group>
          <group group_id="O2">
            <title>A-101 Solution 45</title>
            <description>A-101 Solution 45% administered once per week
A-101 Solution 45</description>
          </group>
        </group_list>
        <measure>
          <title>Durability of Response - Percentage of Participants That Were Clear at Visit 10 That Are Still Clear at Visit 13</title>
          <description>Percentage of subjects whose target wart was clear at Visit 10 and who remained clear at Visit 13 for active treatment groups</description>
          <population>Only the number of participants clear at visit 10 are compared to the number of participants clear at visit 13 to get the percentage clear for active treatment groups only.</population>
          <units>percentage participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="87.50" lower_limit="64.58" upper_limit="99.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PWA Responder</title>
        <description>The percentage of participants who were responders with the target wart judged to be clear (PWA = 0) at Visit 10.</description>
        <time_frame>Day 57</time_frame>
        <population>PP population = participants completing protocol to visit 10</population>
        <group_list>
          <group group_id="O1">
            <title>A-101 Solution 40</title>
            <description>A-101 Solution 40% administered once per week</description>
          </group>
          <group group_id="O2">
            <title>A-101 Solution 45</title>
            <description>A-101 Solution 45% administered once per week</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Solution</title>
            <description>Vehicle Solution administered once per week</description>
          </group>
        </group_list>
        <measure>
          <title>PWA Responder</title>
          <description>The percentage of participants who were responders with the target wart judged to be clear (PWA = 0) at Visit 10.</description>
          <population>PP population = participants completing protocol to visit 10</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13"/>
                    <measurement group_id="O2" value="25.81"/>
                    <measurement group_id="O3" value="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PVal*- Chi-Square test used for calculating P-value by comparing Vehicle against each Active treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9313</p_value>
            <p_value_desc>Not adjusted for multiple comparisons</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0236</p_value>
            <p_value_desc>Not adjusted for multiple comparisons</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>A-101 Solution 40</title>
          <description>A-101 Solution 40% administered once per week
A-101 Solution 40</description>
        </group>
        <group group_id="E2">
          <title>A-101 Solution 45</title>
          <description>A-101 Solution 45% administered once per week
A-101 Solution 45</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Solution</title>
          <description>Vehicle Solution administered once per week
Vehicle Solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <description>Administration site conditions</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Institution and Investigator agree not to publish the results of this study without the prior written consent of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Judy Schnyder, Senior Director of Clinical Operations</name_or_title>
      <organization>Aclaris Therapeutics, Inc.</organization>
      <phone>484-329-2144</phone>
      <email>jschnyder@aclaristx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

